Introduction:

Amiodarone is an antiarrhythmic drug widely used to treat and prevent supraventricular and ventricular arrhythmias. However, it can be associated with various adverse events. In Colombia there are few studies conducted on adverse events with amiodarone.

Objective:

To determine the demographic, clinical and pharmacological characteristics associated with the presence of adverse events in patients with amiodarone use in a cardiovascular clinic in the city of Medellín.

Materials and method:

Retrospective observational analytical cohort study, was conducted by means a review of the clinical records of patients treated with amiodarone during the period from 2008 to 2021. An univariate, bivariate and multivariate analysis was performed through binomial logistic regression.

Results:

A total of 553 medical records were reviewed, of which 221 met the eligibility criteria. The mean age was 63 years and the male sex predominated (57.5%). The majority presented multimorbidity (73.3%), the most common diagnosis for the prescription of amiodarone was atrial fibrillation (84.4%). 71 (32.1%) of adverse events related to amiodarone were reported; being more frequent those of cardiovascular origin (43.7%), followed by thyroid (29.6%) and ophthalmological (10%). The variable that was associated with an adverse event due to amiodarone was multimorbidity (adjusted relative risk [RR] 1.65; IC 95%: 1.02-2.25; p = 0.039).

Conclusions:

Amiodarone adverse events were common. The characteristic that explains 16.8% R²N (Nagelkerke’s R2) adverse event was multimorbidity and the majority of patients required the suspension of treatment.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )